Cencora Inc (COR)

$302.80 +6.48 (2.19%)
Market Cap 57.45B
Revenue (ttm) 293.96B
Net Income (ttm) 1.51B
EPS (ttm) N/A
PE Ratio 19.28
Forward PE 18.75
Profit Margin 0.51%
Debt to Equity Ratio 3.73
Volume 1,429,000
Avg Vol 1,245,300
Day's Range N/A - N/A
Shares Out 193.88M
Stochastic %K 94%
Beta 0.62
Analysts Strong Sell
Price Target $336.21

Company Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management...

Industry: Medical Distribution
Sector: Healthcare
Phone: 610 727 7000
Address:
1 West First Avenue, Conshohocken, United States
Crazyhorse6
Crazyhorse6 Sep. 10 at 4:02 PM
$OTLK $COR
0 · Reply
Rayyleeee
Rayyleeee Sep. 10 at 12:23 PM
$CRWV $COR how much did LEE say he sees CRWV at by the end of next year again?? $400 to $500 $$$$$$
0 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 12:07 PM
$COR is a hold — here’s why ⚖️ Strong GLP-1 and specialty drug growth are fueling gains, but margin pressure and tough competition keep risks in play. Full analysis here 👉 https://www.zacks.com/stock/news/2747443/heres-why-you-should-hold-cencora-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2747443-teaser-11051&ADID=SYND_STOCKTWITS_TWEET_2_2747443_TEASER_11051
0 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 11:07 AM
$COR up 30.3% YTD — what's fueling the growth? 🚀 💊 Strong U.S. Healthcare Solutions & specialty products 📈 EPS climbed 19.8% YoY to $4.00; raised fiscal 2025 outlook 🤝 Acquisition of Retina Consultants expands specialty capabilities Discover what this means for COR's future prospects 👉 https://www.zacks.com/stock/news/2747443/heres-why-you-should-hold-cencora-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2747443-body-11049&ADID=SYND_STOCKTWITS_TWEET_2_2747443_BODY_11049
0 · Reply
Crazyhorse6
Crazyhorse6 Sep. 3 at 2:52 PM
$OTLK There is really only 2 options in my opinion and they are FDA APPROVAL OR BUYOUT/PARTNERSHIP!!! The FDA NEEDS TO BE PUT UNDER A MICROSCOPE!! Besides there is money to be made in those 31 countries that they clearly stated! They are working on 10 other countries as well! Having CENCORA $COR in their back pocket is good! Bob’s background tells me he doesn’t want to look like a chump!!!ONE LAST THING WE ARE IN THE 1 INNING ON COMMERCIALIZATION!! LONG AND STRONG
2 · Reply
StockAutoPro
StockAutoPro Sep. 3 at 1:46 PM
$COR: Buy target $292.85 Sell target $309.59 Strong earnings growth potential observed in leading COR sector software provider.
0 · Reply
StockAutoPro
StockAutoPro Sep. 3 at 3:15 AM
$COR: Buy target $292.85 Sell target $309.59 Significant growth potential observed in a leading waste management company due to increasing sustainability trends.
0 · Reply
AlphaByAI
AlphaByAI Aug. 28 at 5:28 PM
$CAH $MCK $COR Deep dive in three Healthcare stocks. https://newsletter.ai-wk.com/p/healthcare-watchlist-cah-mck-cor
1 · Reply
contangoz
contangoz Aug. 27 at 8:35 PM
$COR NEW CHAIRMAN
0 · Reply
DAODynasty
DAODynasty Aug. 23 at 10:03 AM
$COR Cencora Inc is a pharmaceutical distributor facing margin pressure and regulatory scrutiny
0 · Reply
Latest News on COR
Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 2:05 PM EDT - 1 day ago

Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Cencora, Inc. (COR) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 9, 2025, 6:02 PM EDT - 2 days ago

Cencora, Inc. (COR) Presents At Baird Global Healthcare Conference 2025 Transcript

Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 11:11 AM EDT - 6 days ago

Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

Aug 27, 2025, 4:15 PM EDT - 15 days ago

Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap

Aug 12, 2025, 2:31 PM EDT - 4 weeks ago

Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap

Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy

Aug 8, 2025, 5:08 PM EDT - 4 weeks ago

Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Aug 6, 2025, 12:25 PM EDT - 5 weeks ago

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Cencora raises annual profit forecast on strong demand for specialty drugs

Aug 6, 2025, 7:51 AM EDT - 5 weeks ago

Cencora raises annual profit forecast on strong demand for specialty drugs

Cencora Reports Fiscal 2025 Third Quarter Results

Aug 6, 2025, 6:30 AM EDT - 5 weeks ago

Cencora Reports Fiscal 2025 Third Quarter Results

Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

Jul 3, 2025, 7:30 AM EDT - 2 months ago

Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

May 28, 2025, 7:30 AM EDT - 3 months ago

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs

May 16, 2025, 8:37 AM EDT - 4 months ago

Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

May 7, 2025, 2:06 PM EDT - 4 months ago

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

May 7, 2025, 10:55 AM EDT - 4 months ago

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

Cencora Reports Fiscal 2025 Second Quarter Results

May 7, 2025, 6:30 AM EDT - 4 months ago

Cencora Reports Fiscal 2025 Second Quarter Results

3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

Apr 4, 2025, 3:42 PM EDT - 5 months ago

3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

CVS MCK PM

These 15 stocks are the most profitable companies in the S&P 500

Mar 31, 2025, 7:35 AM EDT - 5 months ago

These 15 stocks are the most profitable companies in the S&P 500

AAPL ABBV AON BA CL CLX DVA

Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

Mar 28, 2025, 7:00 AM EDT - 5 months ago

Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

Cencora: Higher Potential Returns After Reduced Walgreens Stake

Feb 26, 2025, 11:00 AM EST - 7 months ago

Cencora: Higher Potential Returns After Reduced Walgreens Stake

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

Feb 6, 2025, 8:37 PM EST - 7 months ago

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

Feb 6, 2025, 8:30 PM EST - 7 months ago

Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

WBA

Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program

Feb 6, 2025, 8:30 AM EST - 7 months ago

Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program

Cencora (COR) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 11:40 AM EST - 7 months ago

Cencora (COR) Q1 2025 Earnings Call Transcript

Cencora raises 2025 profit forecast on specialty drug demand

Feb 5, 2025, 7:23 AM EST - 7 months ago

Cencora raises 2025 profit forecast on specialty drug demand

Cencora Reports Fiscal 2025 First Quarter Results

Feb 5, 2025, 6:30 AM EST - 7 months ago

Cencora Reports Fiscal 2025 First Quarter Results

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Jan 27, 2025, 7:30 AM EST - 8 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

HROW

Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth

Jan 13, 2025, 12:07 PM EST - 8 months ago

Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth

COST DHR EL MSGS WST

Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

Jan 8, 2025, 7:30 AM EST - 8 months ago

Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

Cencora raises annual profit forecast

Jan 2, 2025, 4:23 PM EST - 9 months ago

Cencora raises annual profit forecast

Cencora Completes Acquisition of Retina Consultants of America

Jan 2, 2025, 4:15 PM EST - 9 months ago

Cencora Completes Acquisition of Retina Consultants of America

Cencora Closes $1.8 Billion Senior Notes Offering

Dec 9, 2024, 4:15 PM EST - 9 months ago

Cencora Closes $1.8 Billion Senior Notes Offering

Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers

Dec 6, 2024, 8:30 AM EST - 9 months ago

Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers

Cencora: Competitive Advantages Defined

Dec 5, 2024, 10:26 AM EST - 10 months ago

Cencora: Competitive Advantages Defined

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

Dec 2, 2024, 10:49 PM EST - 10 months ago

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

Cencora to Host Inaugural Product Showcase

Nov 26, 2024, 8:30 AM EST - 10 months ago

Cencora to Host Inaugural Product Showcase

Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings

Nov 6, 2024, 11:38 AM EST - 11 months ago

Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings

Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript

Nov 6, 2024, 10:56 AM EST - 11 months ago

Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript

Cencora to buy Retina Consultants of America for $4.6 bln

Nov 6, 2024, 6:54 AM EST - 11 months ago

Cencora to buy Retina Consultants of America for $4.6 bln

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

Nov 6, 2024, 6:35 AM EST - 11 months ago

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America

Nov 6, 2024, 6:30 AM EST - 11 months ago

Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America

Cencora Expands Enterprise Leadership Team with Two Senior Appointments

Nov 4, 2024, 8:30 AM EST - 11 months ago

Cencora Expands Enterprise Leadership Team with Two Senior Appointments

Dividend Aristocrats Of The Future - Part 3

Nov 1, 2024, 4:42 PM EDT - 11 months ago

Dividend Aristocrats Of The Future - Part 3

AIZ COST CSX DUK K RSG SRE

Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release

Cencora Supports Pharmaceutical Supply Chain Education with Two New Programs for Health System Pharmacy Residents

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Cencora Supports Pharmaceutical Supply Chain Education with Two New Programs for Health System Pharmacy Residents

Cencora Elects Frank Clyburn to Its Board of Directors

Aug 15, 2024, 7:30 AM EDT - 1 year ago

Cencora Elects Frank Clyburn to Its Board of Directors

Intelliguard, Cencora Partner to Increase Compatibility of RFID-Tagged Medications, Medication Management Systems

Aug 14, 2024, 9:00 AM EDT - 1 year ago

Intelliguard, Cencora Partner to Increase Compatibility of RFID-Tagged Medications, Medication Management Systems

Walgreens continues to shed stake in Cencora as it looks to bolster turnaround

Aug 2, 2024, 1:59 PM EDT - 1 year ago

Walgreens continues to shed stake in Cencora as it looks to bolster turnaround

WBA

Pharma giant Cencora is alerting millions about its data breach

Aug 2, 2024, 10:45 AM EDT - 1 year ago

Pharma giant Cencora is alerting millions about its data breach

Walgreens further reduces stake in Cencora

Aug 1, 2024, 6:20 PM EDT - 1 year ago

Walgreens further reduces stake in Cencora

WBA

Walgreens Boots Alliance Sells Shares of Cencora for Approximately $1.1 Billion of Proceeds

Aug 1, 2024, 6:08 PM EDT - 1 year ago

Walgreens Boots Alliance Sells Shares of Cencora for Approximately $1.1 Billion of Proceeds

WBA

Crazyhorse6
Crazyhorse6 Sep. 10 at 4:02 PM
$OTLK $COR
0 · Reply
Rayyleeee
Rayyleeee Sep. 10 at 12:23 PM
$CRWV $COR how much did LEE say he sees CRWV at by the end of next year again?? $400 to $500 $$$$$$
0 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 12:07 PM
$COR is a hold — here’s why ⚖️ Strong GLP-1 and specialty drug growth are fueling gains, but margin pressure and tough competition keep risks in play. Full analysis here 👉 https://www.zacks.com/stock/news/2747443/heres-why-you-should-hold-cencora-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2747443-teaser-11051&ADID=SYND_STOCKTWITS_TWEET_2_2747443_TEASER_11051
0 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 11:07 AM
$COR up 30.3% YTD — what's fueling the growth? 🚀 💊 Strong U.S. Healthcare Solutions & specialty products 📈 EPS climbed 19.8% YoY to $4.00; raised fiscal 2025 outlook 🤝 Acquisition of Retina Consultants expands specialty capabilities Discover what this means for COR's future prospects 👉 https://www.zacks.com/stock/news/2747443/heres-why-you-should-hold-cencora-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2747443-body-11049&ADID=SYND_STOCKTWITS_TWEET_2_2747443_BODY_11049
0 · Reply
Crazyhorse6
Crazyhorse6 Sep. 3 at 2:52 PM
$OTLK There is really only 2 options in my opinion and they are FDA APPROVAL OR BUYOUT/PARTNERSHIP!!! The FDA NEEDS TO BE PUT UNDER A MICROSCOPE!! Besides there is money to be made in those 31 countries that they clearly stated! They are working on 10 other countries as well! Having CENCORA $COR in their back pocket is good! Bob’s background tells me he doesn’t want to look like a chump!!!ONE LAST THING WE ARE IN THE 1 INNING ON COMMERCIALIZATION!! LONG AND STRONG
2 · Reply
StockAutoPro
StockAutoPro Sep. 3 at 1:46 PM
$COR: Buy target $292.85 Sell target $309.59 Strong earnings growth potential observed in leading COR sector software provider.
0 · Reply
StockAutoPro
StockAutoPro Sep. 3 at 3:15 AM
$COR: Buy target $292.85 Sell target $309.59 Significant growth potential observed in a leading waste management company due to increasing sustainability trends.
0 · Reply
AlphaByAI
AlphaByAI Aug. 28 at 5:28 PM
$CAH $MCK $COR Deep dive in three Healthcare stocks. https://newsletter.ai-wk.com/p/healthcare-watchlist-cah-mck-cor
1 · Reply
contangoz
contangoz Aug. 27 at 8:35 PM
$COR NEW CHAIRMAN
0 · Reply
DAODynasty
DAODynasty Aug. 23 at 10:03 AM
$COR Cencora Inc is a pharmaceutical distributor facing margin pressure and regulatory scrutiny
0 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 1:00 PM
Wells Fargo has adjusted their stance on Cencora ( $COR ), setting the rating to Overweight with a target price of 337 → 354.
0 · Reply
Laynester
Laynester Aug. 12 at 2:39 PM
$CAH $COR BOOOOOO! Lowest [RSI] - and almost....almost....hit the trips. 1.44% and 0.77% dividend on each. That could be .....a good time to buy? Time will tell if the Money Flow returns.... [HOLDING]
0 · Reply
Laynester
Laynester Aug. 8 at 10:20 AM
$COR Has been terrible lately. That and [MCK] both....in fact the lowest on my long term chart RSI (ready for a turnaround??) in the portfolio here. Low RSI means BUY more - need a bit more sector news on that. BOOOOO - "Throw the bums out" - Don't hit my trip on the way out..... BOOOOO!!!!
0 · Reply
StockAutoPro
StockAutoPro Aug. 6 at 8:39 PM
$COR: Buy target $282.08 Sell target $298.28 Strong earnings report indicates potential growth for this leading biopharmaceutical company.
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 6:11 PM
$COR beats Q3 earnings estimates — shares dip pre-market 🤔 Cencora reported an adjusted EPS of $4.00, beating the Zacks Consensus Estimate by 5.8% and showing a 19.8% growth in adjusted EPS year over year. Despite strong segment performance and updated FY25 guidance, shares were down 0.8% in pre-market trading. Full breakdown here 👉 https://www.zacks.com/stock/news/2673444/cor-q3-earnings-revenues-beat-estimates-25-eps-view-raised?cid=sm-stocktwits-2-2673444-body-6273&ADID=SYND_STOCKTWITS_TWEET_2_2673444_BODY_6273
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 1:49 PM
$COR just crushed Q3 — and raised FY25 guidance 💥 Earnings and revenues topped estimates, driven by strong growth in its U.S. segment. Find out what could drive the next leg higher 👉 https://www.zacks.com/stock/news/2673444/cor-q3-earnings-revenues-beat-estimates-25-eps-view-raised?cid=sm-stocktwits-2-2673444-teaser-6268&ADID=SYND_STOCKTWITS_TWEET_2_2673444_TEASER_6268
0 · Reply
kiwitc2000
kiwitc2000 Aug. 6 at 1:42 PM
$COR Earnings beat estimates, and than this happens?? All kinds of garbage runs this morning, but this solid company tanks. Time to add more?
0 · Reply
27R
27R Aug. 5 at 4:49 PM
$COR Earnings release before tomorrow's open. Significant post-earnings volatility expected, but implied vol remains reasonable. Straddle consideration?
0 · Reply
scientificway
scientificway Aug. 5 at 12:27 AM
$COR Loaded, MDXG, huge rev, eps, guidance up. , guidance is so good, how much after a year
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 5:03 PM
$COR earnings preview: Is the streak of surprises ending? 🚨 📊 Despite a strong U.S. Healthcare Solutions segment, Cencora's Earnings ESP is 0.00%, suggesting an earnings beat is unlikely this time. 🔍 Specialty volumes remain robust, but international segment weakness could weigh on results. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2663057/can-specialty-and-glp-1-momentum-support-cencoras-q3-results?cid=sm-stocktwits-2-2663057-body-5800&ADID=SYND_STOCKTWITS_TWEET_2_2663057_BODY_5800
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 3:59 PM
$COR riding GLP-1 tailwinds — but will it be enough? 💊📉 Specialty and GLP-1 momentum is a clear driver, but international softness could weigh on Q3 results. Full breakdown here 👉 https://www.zacks.com/stock/news/2663057/can-specialty-and-glp-1-momentum-support-cencoras-q3-results?cid=sm-stocktwits-2-2663057-teaser-5741&ADID=SYND_STOCKTWITS_TWEET_2_2663057_TEASER_5741
0 · Reply